All Stories

  1. Cost-effectiveness of fecal immunochemical testing for colorectal cancer in Mexico City: A microsimulation modeling study
  2. A Tutorial on Discrete Event Simulation Models Using a Cost-Effectiveness Analysis Example in R
  3. A Microsimulation-Based Approach for Mitigating Societal Bias in Chronic Kidney Disease Data
  4. PRE-CISE: A PRE-calibration Coverage, Identifiability, and SEnsitivity analysis workflow to streamline model calibration
  5. A Novel Decision-Modeling Framework for Health Policy Analyses When Outcomes Are Influenced by Social and Disease Processes
  6. Differences in Bladder Cancer Diagnosis by Demographic Factors: A Simulation Modeling Analysis
  7. The best screening test is the one that gets followed up on
  8. Discrete-Event Simulation Modeling Framework for Cancer Interventions and Population Health in R (DESCIPHR): An Open-Source Pipeline
  9. Bladder Cancer Burden in the USA: Population Scenarios for 2040
  10. The cost of non-drug interventions that improve function and reduce dementia-related behaviors
  11. Public-health impact of increasing human papillomavirus vaccination and cervical cancer screening
  12. Reply to: Comment on Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness
  13. Data from Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study
  14. Supplementary Figure S1 from Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study
  15. Supplementary Figure S2 from Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study
  16. Supplementary Table S1 from Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study
  17. Long-term trends in bladder cancer incidence using a harmonized staging variable – A SEER-based study
  18. Benefits of colorectal cancer screening using FIT with varying positivity thresholds by age and sex
  19. Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer
  20. A Tutorial on Discrete Event Simulation Models in R Using a Cost-Effectiveness Analysis Example
  21. Discrete-Event Simulation Model for Cancer Interventions and Population Health in R (DESCIPHR): An Open-Source Pipeline
  22. Calculating epidemiological outcomes from simulated longitudinal data
  23. Cost-Effectiveness of Using Conditional Economic Incentives to Improve Pre-exposure Prophylaxis Adherence Among Male Sex Workers
  24. A microsimulation-based framework for mitigating societal bias in primary care data
  25. Cost-effectiveness of enfortumab vedotin and pembrolizumab for first-line metastatic urothelial cancer in the United States
  26. Utility Values of Health Status in Gastric Cancer: A Systematic Review
  27. A novel decision modeling framework for health policy analyses when outcomes are influenced by social and disease processes
  28. A Fast Nonparametric Sampling Method for Time to Event in Individual-Level Simulation Models
  29. Microsimulation Estimates of Decision Uncertainty and Value of Information Are Biased but Consistent
  30. State-level disparities in cervical cancer prevention and outcomes in the U.S.: a modeling study
  31. Primary HPV screening compared with other cervical cancer screening strategies in women with HIV: a cost-effectiveness study
  32. Helicobacter pylori infection in the United States beyond NHANES: a scoping review of seroprevalence estimates by racial and ethnic groups
  33. Birth cohort and age-specific trends in global Helicobacter pylori seroprevalence: a scoping review
  34. Incentivizing adherence to pre-exposure prophylaxis for HIV prevention: a randomized pilot trial among male sex workers in Mexico
  35. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision
  36. State-level disparities in cervical cancer prevention and impact on outcomes in the U.S.: A modeling study
  37. Emulator-Based Bayesian Calibration of the CISNET Colorectal Cancer Models
  38. Characteristics of a cost-effective blood test for colorectal cancer screening
  39. A Fast Nonparametric Sampling (NPS) Method for Time-to-Event in Individual-Level Simulation Models.
  40. Using Age-Specific Rates for Parametric Survival Function Estimation in Simulation Models
  41. Value of Information: Success Stories
  42. Effects of Mitigation and Control Policies in Realistic Epidemic Models Accounting for Household Transmission Dynamics
  43. Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program
  44. NordICC Trial Results in Line With Expected Colorectal Cancer Mortality Reduction After Colonoscopy: A Modeling Study
  45. Breastfeeding is associated with the intelligence of school‐age children in Mexico
  46. Cost effectiveness of non‐drug interventions that reduce nursing home admissions for people living with dementia
  47. Emulator-based Bayesian calibration of the CISNET colorectal cancer models
  48. Effects of Mitigation and Control Policies in Realistic Epidemic Models Accounting for Household Transmission Dynamics
  49. A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example
  50. Dynamics of Respiratory Infectious Diseases in Incarcerated and Free-Living Populations: A Simulation Modeling Study
  51. An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example
  52. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison
  53. Characterization and Valuation of the Uncertainty of Calibrated Parameters in Microsimulation Decision Models
  54. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis
  55. Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study
  56. Retention in Care, Mortality, Loss-to-Follow-Up, and Viral Suppression among Antiretroviral Treatment-Naïve and Experienced Persons Participating in a Nationally Representative HIV Pre-Treatment Drug Resistance Survey in Mexico
  57. Age-specific rates of onset of cannabis use in Mexico
  58. Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies
  59. Effectiveness of COVID-19 Vaccines among Incarcerated People in California State Prisons: A Retrospective Cohort Study
  60. COVID-19 in the California State Prison System: an Observational Study of Decarceration, Ongoing Risks, and Risk Factors
  61. Dependence of COVID-19 Policies on End-of-Year Holiday Contacts in Mexico City Metropolitan Area: A Modeling Study
  62. Prioritizing Research Informing Antibiotic Prophylaxis Guidelines for Knee Arthroplasty Patients
  63. BayCANN: Streamlining Bayesian Calibration With Artificial Neural Network Metamodeling
  64. Covid-19 Vaccine Acceptance in California State Prisons
  65. Outbreaks of Covid-19 Variants in Prisons: A Mathematical Modeling Analysis of Vaccination and Re-Opening Policies
  66. Covid-19 in the California State Prison System: An Observational Study of Decarceration, Ongoing Risks, and Risk Factors
  67. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries
  68. How do Covid-19 policy options depend on end-of-year holiday contacts in Mexico City Metropolitan Area? A Modeling Study
  69. Age-Specific Rates of Onset of Cannabis Use in Mexico
  70. The Household Secondary Attack Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Rapid Review
  71. A Summary of the 2020 Gastric Cancer Summit at Stanford University
  72. Estimating population-based recurrence rates of colorectal cancer over time in the United States
  73. Cost-effectiveness analysis of a multidisciplinary health-care model for patients with type-2 diabetes implemented in the public sector in Mexico: A quasi-experimental, retrospective evaluation
  74. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests
  75. Validation of Microsimulation Models Used for Population Health Policy
  76. Discussing Cervical Cancer Screening Options: Outcomes to Guide Conversations Between Patients and Providers
  77. Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods
  78. Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies
  79. A Multidimensional Array Representation of State-Transition Model Dynamics
  80. Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis
  81. Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio
  82. Midwife‐led care and obstetrician‐led care for low‐risk pregnancies: A cost comparison
  83. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer
  84. A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management
  85. A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling
  86. A Multidimensional Array Representation of State-Transition Model Dynamics
  87. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies
  88. “Time Traveling Is Just Too Dangerous” but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier
  89. The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis
  90. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer
  91. Nonidentifiability in model calibration and its implications for medical decision making.
  92. Revisiting assumptions about age-based sexual mixing representations in mathematical models
  93. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis
  94. Force of infection of Helicobacter pylori in Mexico: evidence from a national survey using a hierarchical Bayesian model – CORRIGENDUM
  95. Force of infection of Helicobacter pylori in Mexico: evidence from a national survey using a hierarchical Bayesian model
  96. Microsimulation modeling in R: A tutorial
  97. A Kinked Health Insurance Market: Employer-Sponsored Insurance under the Cadillac Tax
  98. A Gaussian Approximation to efficiently compute the expected value of sample information (EVSI)
  99. Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis
  100. Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?
  101. An Overview of R in Health Decision Sciences
  102. Modeling the Cost-Effectiveness of Doula Care Associated with Reductions in Preterm Birth and Cesarean Delivery
  103. Análisis de costo-beneficio: prevención del VIH/sida en migrantes en Centroamérica
  104. Registro de señales de EEG para aplicaciones de Interfaz Cerebro Computadora (ICC) basado en Potenciales Evocados Visuales de Estado Estacionario (PEVEE)